January 30th 2025
Biocontainment, including the most recent threat of highly pathogenic avian influenza, demands we continue to finance research, and continue cooperation with important organizations like the WHO.
Despite 60% Drop in Hepatitis B Treatment Efficacy, GSK Plans to Continue Trials
November 9th 2022Initially, 28-29% of patients with chronic hepatitis B achieved undetectable virus levels after 24 weeks of treatment with GSK’s bepirovirsen, but this dropped to 9-10% of patients during a phase 2b trial.
Read More
HCV Reinfection Rare Among Patients Receiving Opioid Agonist Therapy
August 24th 2022Rates of hepatitis C reinfection were low among people receiving opioid agonist therapy, according to a new study, which highlights the importance of risk reduction interventions and HCV treatment for people who inject drugs and people receiving opioid agonist therapy.
Read More